MoonLake Immunotherapeutics is developing sonelokimab, an investigational therapy targeting inflammatory diseases such as hidradenitis suppurativa, psoriatic arthritis, and axial spondyloarthritis.

TEL AVIV, Israel, April 02, 2026 (GLOBE NEWSWIRE)-- Entera Bio Ltd. (Nasdaq: ENTX) ("Entera" or the "Company"), a leader in the development of oral peptides, today announced that it has entered into a ...

- Series A financing co-led by Bain Capital Life Sciences, BVF Partners and Third Rock Ventures CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merida Biosciences, a biotechnology company pioneering a new class of ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) (“Infinity”) today announced a $20 million non-dilutive asset-backed financing ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Anelixis Therapeutics Inc. Anelixis Therapeutics, Inc., “Anelixis” is a clinical stage development company with a portfolio of antibodies blocking CD40 Ligand (CD40L ...

Biotechnology Value Fund, which holds a 30 percent stake in Avigen, will finally get that special shareholders meeting it's been pushing for later this month. The firm is urging fellow stockholders to ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

On April 2, 2026, MoonLake Immunotherapeutics (NASDAQ:MLTX) BVF Partners L.P. reported the direct sale of 3,750,000 shares of Common Stock for a total consideration of approximately $62.96 million, ...